A number of other analysts have also recently weighed in on the stock. Goldman Sachs Group assumed coverage on shares of Myovant Sciences in a report on Friday, October 26th. They set a neutral rating and a $25.00 target price on the stock. Zacks Investment Research raised shares of Myovant Sciences from a sell rating to a hold rating in a report on Wednesday, October 10th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Myovant Sciences in a report on Thursday, September 13th. They set an overweight rating and a $39.00 target price on the stock. Three analysts have rated the stock with a hold rating and five have given a buy rating to the stock. Myovant Sciences presently has a consensus rating of Buy and an average price target of $29.20.
NYSE MYOV traded down $2.23 during trading hours on Friday, reaching $19.06. 81,976 shares of the company traded hands, compared to its average volume of 59,557. Myovant Sciences has a 12 month low of $11.30 and a 12 month high of $27.45. The company has a debt-to-equity ratio of 0.73, a current ratio of 3.07 and a quick ratio of 3.07. The company has a market capitalization of $1.46 billion, a price-to-earnings ratio of -7.91 and a beta of 0.12.
Myovant Sciences (NYSE:MYOV) last posted its quarterly earnings data on Thursday, November 8th. The company reported ($0.99) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.93) by ($0.06). As a group, analysts anticipate that Myovant Sciences will post -3.91 EPS for the current year.
In other Myovant Sciences news, Director Mark Altmeyer bought 3,500 shares of the company’s stock in a transaction on Saturday, November 17th. The shares were bought at an average cost of $13.38 per share, with a total value of $46,830.00. Following the completion of the acquisition, the director now owns 3,500 shares of the company’s stock, valued at $46,830. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.10% of the stock is currently owned by corporate insiders.
Several hedge funds have recently added to or reduced their stakes in the stock. BB Biotech AG boosted its holdings in Myovant Sciences by 1.7% during the third quarter. BB Biotech AG now owns 3,567,882 shares of the company’s stock worth $94,727,000 after buying an additional 60,000 shares in the last quarter. Opera Trading Capital purchased a new stake in Myovant Sciences during the third quarter worth about $117,000. Janus Henderson Group PLC boosted its holdings in Myovant Sciences by 124.8% during the third quarter. Janus Henderson Group PLC now owns 2,525,193 shares of the company’s stock worth $67,044,000 after buying an additional 1,401,796 shares in the last quarter. Atria Investments LLC purchased a new stake in Myovant Sciences during the third quarter worth about $201,000. Finally, Millennium Management LLC boosted its holdings in Myovant Sciences by 79.1% during the second quarter. Millennium Management LLC now owns 191,436 shares of the company’s stock worth $4,378,000 after buying an additional 84,568 shares in the last quarter. 21.04% of the stock is currently owned by institutional investors and hedge funds.
About Myovant Sciences
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
See Also: How to calculate compound interest
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.